Menu Search
Equities

Creative Medical Technology Holdings Inc

CELZ:NAQ

Creative Medical Technology Holdings Inc

Actions
FinancialsInvestment Banking and Brokerage Services
  • Price (USD)3.12
  • Today's Change0.01 / 0.32%
  • Shares traded93.25k
  • 1 Year change-39.42%
  • Beta5.0406
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Creative Medical Technology Holdings Inc had revenues fall -89.84% from 88.60k to 9.00k, though the company grew net income from a loss of 10.14m to a smaller loss of 5.29m.
Gross margin60.00%
Net profit margin-33,716.41%
Operating margin-35,667.59%
Return on assets-51.83%
Return on equity-53.71%
Return on investment-53.71%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Creative Medical Technology Holdings Inc fell by 4.85m. However, Cash Flow from Investing totalled 3.45m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 8.03m for operations while cash used for financing totalled 270.95k.
Cash flow per share-3.99
Price/Cash flow per share--
Book value per share5.69
Tangible book value per share5.40
More ▼

Balance sheet in USDView more

Creative Medical Technology Holdings Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio20.21
Quick ratio20.20
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.